Skip to main content
Year archive

PRESCIENT THERAPEUTICS LIMITED — 2023 filings

All 36 regulatory filings released by PRESCIENT THERAPEUTICS LIMITED (PTX) in 2023, sourced directly from the official regulator.

36 Filings
2023 Period
2023 filings (36)
Filing Released Lang
PTX-100 Spotlight Presentation 30 pages 1.5MB
Investor Presentation
2023-12-17 English
PTX-100 Ph1b results show excellent safety & efficacy in TCL 6 pages 1.4MB
Regulatory Filings
2023-12-10 English
Prescient Receives $2.4 Million R&D Tax Rebate 3 pages 638.1KB
Regulatory Filings
2023-11-27 English
Chair and CEO AGM Presentation 46 pages 16.4MB
AGM Information
2023-11-15 English
Results of Annual General Meeting 2 pages 508.0KB
Declaration of Voting Results & Voting Rights Announcements
2023-11-15 English
PTX-100 abstract published online on ASH website 3 pages 640.6KB
Regulatory Filings
2023-11-05 English
September 2023 Quarterly Update and Appendix 4C 12 pages 1.5MB
Interim / Quarterly Report
2023-10-30 English
PTX results to be presented at world's largest blood meeting 4 pages 1.2MB
Regulatory Filings
2023-10-16 English
Notice of Annual General Meeting/Proxy Form 20 pages 1.4MB
AGM Information
2023-10-12 English
Section 708A Cleansing Notice 2 pages 539.5KB
Capital/Financing Update
2023-08-30 English
Application for quotation of securities - PTX 6 pages 28.0KB
Share Issue/Capital Change
2023-08-30 English
Appendix 4E and 2023 Annual Report 55 pages 2.5MB
Annual Report
2023-08-24 English
Appendix 4G and Corporate Governance Statement 25 pages 1.6MB
Regulatory Filings
2023-08-24 English
June 2023 Quarterly Update and Appendix 4C 13 pages 6.9MB
Interim / Quarterly Report
2023-07-26 English
Application for quotation of securities - PTX 6 pages 28.0KB
Share Issue/Capital Change
2023-06-13 English
Two PTX abstracts accepted at prestigious ISCT conference 4 pages 946.1KB
Regulatory Filings
2023-05-15 English
Experienced Pharma Executive Joins Prescient Board 4 pages 1.2MB
Board/Management Information
2023-05-14 English
Notification regarding unquoted securities - PTX 7 pages 30.9KB
Share Issue/Capital Change
2023-05-14 English
Initial Director's Interest Notice 2 pages 267.9KB
Director's Dealing
2023-05-14 English
Notification of cessation of securities - PTX 4 pages 24.6KB
Share Issue/Capital Change
2023-05-04 English
Change of Director's Interest Notices x3 8 pages 528.6KB
Director's Dealing
2023-05-01 English
Section 708A Cleansing Notice 2 pages 511.1KB
Regulatory Filings
2023-04-30 English
Application for quotation of securities - PTX 6 pages 28.9KB
Share Issue/Capital Change
2023-04-30 English
March 2023 Quarterly Update and Appendix 4C 13 pages 1.6MB
Interim / Quarterly Report
2023-04-27 English
Exercise and Expiry of Listed Options 3 pages 963.5KB
Capital/Financing Update
2023-04-03 English
Application for quotation of securities - PTX 6 pages 28.0KB
Share Issue/Capital Change
2023-04-03 English
Change of Director's Interest Notices x2 7 pages 411.7KB
Director's Dealing
2023-04-03 English
Continued promising results in PTX-100 TCL trial 7 pages 2.2MB
Regulatory Filings
2023-03-15 English
FDA grants broader orphan drug status to PTX100 for TCLs 4 pages 915.2KB
Regulatory Filings
2023-03-08 English
Revised Securities Trading Policy 10 pages 1.1MB
Governance Information
2023-02-26 English
Appendix 4D and Half Year Financial Report 22 pages 1.6MB
Interim / Quarterly Report
2023-02-23 English
Notification of Expiry of Listed Options 5 pages 2.2MB
Share Issue/Capital Change
2023-02-21 English
Application for quotation of securities - PTX 6 pages 27.9KB
Share Issue/Capital Change
2023-02-08 English
Application for quotation of securities - PTX 6 pages 27.9KB
Share Issue/Capital Change
2023-01-24 English
December 2022 Quarterly Update and Appendix 4C 10 pages 1.2MB
Interim / Quarterly Report
2023-01-24 English
Application for quotation of securities - PTX 6 pages 27.9KB
Share Issue/Capital Change
2023-01-04 English